Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2

Autor: A.N. Boyko, V.M. Alifirova, I.G. Lukashevich, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, N.A. Malkova, G.N. Mishin, E.V. Parshina, I.Ye. Poverennova, L.N. Prakhova, S.A. Sivertseva, I.V. Smagina, N.A. Totolyan, Yu.V. Trinitatsky, T.N. Trushnikova, F.A. Khabirov, S.G. Shchur, A.V. Artemyeva, D.D. Bolsun, A.V. Zinkina-Orikhan, Yu.N. Linkova
Rok vydání: 2023
Předmět:
Zdroj: Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 123:37
ISSN: 1997-7298
DOI: 10.17116/jnevro202312304137
Databáze: OpenAIRE